CAPRELSA

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug CAPRELSA contains one active pharmaceutical ingredient (API):

1	Vandetanib UNII YO460OQ37K - VANDETANIB
	Vandetanib is a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2 also known as kinase insert domain containing receptor [KDR]), epidermal growth factor receptor (EGFR) and RET tyrosine kinases. Vandetanib is also a sub-micromolar inhibitor of vascular endothelial receptor-3 tyrosine kinase.
	Read more about Vandetanib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CAPRELSA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX04	Vandetanib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	502313020022501, 502313020022601, 576720050064717, 576720050064817
CA	Health Products and Food Branch	02378582, 02378590
EE	Ravimiamet	1556759, 1556760
ES	Centro de información online de medicamentos de la AEMPS	11749001, 11749002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	416002, 468773
FR	Base de données publique des médicaments	65808531, 69269825
GB	Medicines & Healthcare Products Regulatory Agency	203587, 203590
HK	Department of Health Drug Office	62086, 62087
IE	Health Products Regulatory Authority	88786, 88787
IL	מִשְׂרַד הַבְּרִיאוּת	7139
JP	医薬品医療機器総合機構	4291041F1029
LT	Valstybinė vaistų kontrolės tarnyba	1065206, 1065207
NL	Z-Index G-Standaard, PRK	101516, 101524
PL	Rejestru Produktów Leczniczych	100267875, 100267881
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W62995001, W62996001
US	FDA, National Drug Code	58468-7820, 58468-7840